Sadly, Sanofi and Mannkind have disbanded their licensing agreement for Afrezza following poor US sales. The press release from Mannkind states:
VALENCIA, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today announced the termination of its license and collaboration agreement with sanofi-aventis U.S. LLC for the development and commercialization of Afrezza® (insulin human) Inhalation Powder. The parties will promptly commence transition discussions in order to effect a smooth and orderly transition in the development and commercialization of Afrezza from Sanofi to MannKind over the next 90 - 180 days. In any event, termination of the license agreement in its entirety will be effective no later than six months from the effective date of Sanofi's notice of termination, or July 4, 2016.
MannKind is reviewing its strategic options for Afrezza as a result of the termination of the collaboration with Sanofi.
- See more at: http://investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=948810#sthash.wy4kv2S2.dpuf
I've written a bit of a commentary on this on my blog.
VALENCIA, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today announced the termination of its license and collaboration agreement with sanofi-aventis U.S. LLC for the development and commercialization of Afrezza® (insulin human) Inhalation Powder. The parties will promptly commence transition discussions in order to effect a smooth and orderly transition in the development and commercialization of Afrezza from Sanofi to MannKind over the next 90 - 180 days. In any event, termination of the license agreement in its entirety will be effective no later than six months from the effective date of Sanofi's notice of termination, or July 4, 2016.
MannKind is reviewing its strategic options for Afrezza as a result of the termination of the collaboration with Sanofi.
- See more at: http://investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=948810#sthash.wy4kv2S2.dpuf
I've written a bit of a commentary on this on my blog.
